Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Genes required for B cell development
Mary Ellen Conley
Mary Ellen Conley
Published December 1, 2003
Citation Information: J Clin Invest. 2003;112(11):1636-1638. https://doi.org/10.1172/JCI20408.
View: Text | PDF
Commentary

Genes required for B cell development

  • Text
  • PDF
Abstract

Mutations in a variety of genes can cause congenital agammaglobulinemia and a failure of B cell development. The currently known genes encode components of the pre–B cell receptor or proteins that are activated by cross-linking of the pre–B cell receptor. Defects in these genes result in a block in B cell differentiation at the pro–B to pre–B cell transition. A patient with a translocation involving a previously unknown gene, LRRC8, demonstrated a block at exactly the same point in B cell differentiation (see the related article beginning on page 1707). It will be interesting to determine whether the protein encoded by this gene interacts with the pre–B cell receptor signal transduction pathway or is involved in a new pathway.

Authors

Mary Ellen Conley

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Early stages of B cell differentiation can be identified by the status o...
Early stages of B cell differentiation can be identified by the status of the Ig genes and by the cell surface markers CD34, CD19, and surface Ig (sIg). In stem cells and common lymphoid precursors, the Ig genes are in germ-line configuration. These cells express CD34 but not CD19 or sIg. In pro–B cells, cells committed to the B cell lineage, the first step in μ heavy chain gene rearrangement, D-to-J rearrangement, is occurring. All of the components of the pre–B cell receptor except μ heavy chain (the surrogate light chain proteins λ5 and VpreB, and the proteins that constitute the pre–B cell receptor signal transduction module, Igα and Igβ) can be found in the cytoplasm of these cells. Pro–B cells are positive for CD34 and CD19, but they are negative for sIg. Once an effective, in-frame VDJ heavy chain rearrangement has occurred, and the resulting μ heavy chaine light chain genes are in germ-line configuration. These cells express cytoplasmic μ heavy chain and cell surface CD19, but they are negative for CD34 and sIg. After successful rearrangement of a light chain gene, the conventional B-cell receptor can be expressed on the cell surface, and the cell becomes an immature B cell that is positive for CD19 and sIg and negative for CD34.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts